This is a prospective, single arm, phase II trail to assess the effect of primary lesion radiotherapy in the treatment of stage IVB cervical cancer on the basis of systemic chemotherapy.
Because of the apparent heterogeneity of stage IVB cervical cancer, at present there is no standard treatment. This is a Phase II, single-center, single-arm, study of systemic chemotherapy plus lesion radiotherapy for primary stage IVB cervical cancer. The primary objective of the study is to test the hypothesis that primary lesion radiotherapy leads to an improvement in progression-free survival time (PFS)for stage IVB cervical cancer. For those patients under the clinical management of the recruiting investigator, the investigator will review the patient's medical records and determine if they would be a candidate for the study. Upon confirmation of all eligibility criteria, the subject will be enrolled.Patients with beyond abdominal pelvic lymph node metastasis will first undergo 2 cycle systemic chemotherapy(TP/TC),then to evaluate the efficacy of chemotherapy, and for patients with chemotherapy effective(CR+PR+SD) followed by the primary lesion of regional radiotherapy (external irradiation plus brachytherapy),concurrent chemotherapy (TP/TC) may be given according to the patients tolerant,finally, the patient will complete a total of 6 cycles of chemotherapy(TP/TC).Distant metastasis of lymph node areas (e.g., supraclavicular, axillary, mediastinum, etc.) will be radiation after radiotherapy at the primary site according to patients tolerant.Patients with stage IVB cervical cancer with hematogenous metastasiswill first undergo 4 cycle systemic chemotherapy(TP/TC),then to evaluate the efficacy of chemotherapy, and for patients with chemotherapy effective(CR+PR+SD) followed by the primary lesion of regional radiotherapy (external irradiation plus brachytherapy),concurrent chemotherapy (TP/TC) may be given according to the patients tolerant,finally, the patient will complete a total of 6 cycles of chemotherapy(TP/TC),after the primary radiotherapy, the treatment regimen for distant metastasis will be determined by MDT discuss or consultation.Quality of life will be evaluated before and after treatment. During therapy, the patient will have a weekly physical exam, vital signs collected, evaluation for pain, and review any side effects. Subjects will undergo a post treatment follow-up period after completion of their radiation therapy. During this follow-up period, subjects will return for a medical and history review with a complete physical examination, review of any side effects, evaluation for outcomes and toxicity, and QoL.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
48
Pelvic,pelvic-inguinal,or extended field radiotherapy:Therapy 45 - 50 Gy in 1.7 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks for PTV Brachytherapy: Therapy 5-6 fractions of 4-6Gy prescribed to the high-risk CTV or A piont.
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
RECRUITINGProgression-free survival time, PFS
Progression-free survival will be evaluated
Time frame: 2 years
Number of Patients with Adverse Events as a Measure of Safety
To quantify rates of acute hematologic, gastrointestinal, and genitourinary toxicity
Time frame: 2 years
Objective Response Rates, ORR
Objective Response Rates will be evaluated
Time frame: 2 years
Overall survival
Overall survival will be evaluated
Time frame: 2 years
Ranking Quality of Life of Patients
To measure health-related quality of life based on the cancer-specific EORTC-QLQ-C30 questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and cervical cancer module(CX24).
Time frame: 2 years
Screening for potentially curable primary stage IVB cervical cancer
By follow-up data,screening for potentially curable primary stage IVB cervical cancer
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.